The <ENAMEX TYPE="ORGANIZATION">University</ENAMEX> of <ENAMEX TYPE="LOCATION">Toronto</ENAMEX> stepped deeper into the contest for Connaught Biosciences <ENAMEX TYPE="ORGANIZATION">Inc</ENAMEX> by reaching an unusual agreement with <ENAMEX TYPE="ORGANIZATION">Ciba Geigy Ltd</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron Corp</ENAMEX> The <ENAMEX TYPE="ORGANIZATION">University</ENAMEX> said the two companies agreed to spend 25 million Canadian dollars 21 3 million over 10 years on research at Canadian universities if they are successful in acquiring the vaccine maker It said 10 million would go to the <ENAMEX TYPE="ORGANIZATION">University</ENAMEX> of <ENAMEX TYPE="LOCATION">Toronto Ciba Geigy</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX> have made a joint bid of C 866 million for Connaught and Institut Merieux S A of <ENAMEX TYPE="LOCATION">France</ENAMEX> has made a rival bid of C 942 million The <ENAMEX TYPE="ORGANIZATION">University</ENAMEX> is seeking an injunction against the Merieux bid arguing that Connaught s predecessor company agreed in 1972 that Connaught s ownership wouldn t be transferred to foreigners The university implied that it would drop its opposition to foreign ownership if Ciba Geigy and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX> are successful with their lower bid It said the new agreement would replace the old one that forms the basis of its suit against the Merieux takeover Notwithstanding foreign ownership of Connaught this accord would enhance research and development in <ENAMEX TYPE="LOCATION">Canada</ENAMEX> said <ENAMEX TYPE="PERSON">James Keffer</ENAMEX> the university s vice president of research Ciba Geigy is a Swiss pharmaceutical company and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX> is based in <ENAMEX TYPE="LOCATION">Emeryville Calif</ENAMEX> In a statement <ENAMEX TYPE="PERSON">Jacques Francois Martin</ENAMEX> director general of Merieux said the French company is still determined to acquire Connaught While he didn t comment directly on the pact between Ciba Geigy and the university he said Merieux can transfer new products and technologies to Connaught more rapidly than other companies not currently producing and marketing vaccines who can only promise this for some years in the future In national over the counter trading yesterday Connaught closed at 28 625 up 1 25